Unlike opium, nitazenes and other synthetic opioids can be produced anywhere in the world using precursor chemicals that are often uncontrolled.

Racial disparities in mortality are increasing. This article explores how the production of DNA-edited ethnically diverse ...

For the first time in 20 years, the Food and Drug Administration has approved a new pharmaceutical approach to treating pain.

The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...